Auricular Acupuncture
OtherAuricular acupuncture
NCT Number: NCT07024511
Migraine is a primary headache disorder characterized by recurrent episodes of moderate to severe pain, frequently accompanied by nausea, photophobia, and phonophobia. It ranks as the third most prevalent medical condition globally and is recognized by the World Health Organization (WHO) as one of the top ten causes of disability worldwide. Migraine presents substantial public health concerns due to its considerable socioeconomic burden and its detrimental impact on individuals' quality of life. Although pharmacological treatments are widely available, their effectiveness is often limited, with many patients experiencing inadequate symptom relief or adverse side effects. Consequently, there has been growing interest in non-pharmacological approaches, particularly acupuncture and auricular therapy, due to their favorable safety profiles and reported efficacy in alleviating migraine symptoms. Auricular therapy, a microsystem of acupuncture applied to specific points on the external ear, has gained popularity for its simplicity, low risk, and therapeutic potential. Despite its increasing clinical use, robust scientific evidence supporting the effectiveness of auricular therapy for migraine remains insufficient, underscoring the need for well-designed clinical studies to validate its therapeutic value.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Not applicable
Hebei University of Engineering Affiliated Hospital, Handan, Hebei, China
Migraine is a complex and dynamic neurological disorder characterized by fluctuations in attack frequency, duration, severity, and associated symptoms, necessitating timely prevention and effective management strategies. While pharmacological treatments remain the mainstay, their limitations have led to increasing interest in non-pharmacological interventions such as acupuncture. Acupuncture has gained global recognition for its efficacy, particularly in migraine, which is one of the conditions most responsive to this therapy. Supported by strong clinical evidence, acupuncture is considered safe and well-tolerated, with a low incidence of adverse effects. Guidelines for managing primary headache disorders now advocate a range of complementary approaches, including acupuncture, dietary changes, physical activity, and cognitive behavioral therapy which reflecting a paradigm shift towards integrative care. Clinical studies have demonstrated that acupuncture can significantly reduce migraine frequency, shorten attack duration, and alleviate symptom severity. Mechanistic research suggests acupuncture modulates migraine pathophysiology through neuroimmune and neurotransmitter regulation, although further studies are needed to elucidate its molecular effects, particularly beyond the trigeminovascular system. Within Traditional Chinese Medicine, auricular therapy based on stimulating specific points on the external ear aligned with internal organ systems via the "inverted fetus" model offers a simplified, non-invasive modality that activates neural signaling pathways to regulate bodily functions and relieve migraine symptoms. Despite its growing clinical use, further clinical evidence is needed to confirm the therapeutic efficacy and mechanisms of auricular acupuncture in migraine management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Auricular acupuncture
Acupuncture
Time frame: from baseline to 1 month post treatment.
The frequency of headaches will be recorded in the form of a headache diary, and doctors will conduct electronic inquiries in WeChat groups every day.
Time frame: from baseline to 1 month post treatment.
Pain severity is categorized as follows: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). The score is determined by measuring the distance (in millimeters) on a 10 cm line between the "no pain" anchor and the patient's mark using a ruler, providing a score range of 0 to 100.
Time frame: from baseline to 1 month post treatment
The Migraine Disability Assessment (MIDAS) questionnaire consists of five questions, each addressing the number of days affected by migraines. The average pain intensity of headaches is rated on a scale from 0 to 10, where 0 indicates no pain and 10 represents the most severe pain.
Time frame: from baseline to 1 month post treatment
The Migraine-Specific Quality of Life Questionnaire (MSQ) comprises 3 domains: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Each item is scored on a 1-6 scale.
Raw dimension scores are computed as a sum of item responses and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life.
Time frame: from baseline to 1 month post treatment
Time frame: at immediate post treatment
Patients Global Impression of Improvement (PGI-I) is a transition scale that is a single question asking the patient to rate their condition, as compared with how it is prior to before beginning treatment on a scale. This is measured by success , where it is defined as "very much improved" or "much improved".
Time frame: from baseline to immediate post treatment
RDW testing is a part of blood routine and usually does not require special preparation. Patients do not need to be on an empty stomach. To ensure that blood indicators are not affected by time, all patients will have their blood drawn at 10am on the day after the end of treatment
Time frame: up to 48 hours after each treatment
including bleeding, subcutaneous hemorrhage, hematoma, fainting, serious pain, and local infection
Contact information is provided by the study sponsor or research team.
Universiti Tunku Abdul Rahman
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07651839
Anxiety, Anxiety Disorders
View Trial DetailsNCT07479212
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
View Trial DetailsNCT07451769
Adrenomedullin, Brain Diseases
Glostrup Municipality, Denmark
View Trial DetailsNCT07261384
Brain Diseases, Central Nervous System Diseases
Erzincan, Turkey (Türkiye)
View Trial Details